Normal Human Pancreas



Supplementary figure 1: Flow cytometry performed on normal human pancreas samples (N=4). A representative flow plot shows 2.89% CD45⁺ cells infiltrating the normal human pancreas (gating is performed using isotype control).

NORMAL HUMAN PANCREAS (40X) BROWN=CD 14



HUMAN PANCREATIC CANCER



Supplementary figure 2: Immunohistochemistry images (40X) of PC tumor specimens (N=5) and normal human pancreas (N=5) stained for CD14⁺ cells (Brown). Arrows point towards CD14⁺ cells in the tumor.



Supplementary figure 3:

A scatter plot comparing ALDH1^{Bright} cells as percent of EpCAM positive cells in PC and normal human pancreas by flow cytometry. The ALDH1^{Bright} population (as percent of EpCAM positive cells) is significantly higher in PC compared to Normal human pancreas (p=<0.05 by Mann Whitney test).

Correlation between CD14+ infiltrate and ALDH1 expression



Supplementary Figure 4: Pearson correlation analysis shows a significant positive correlation of percent CD14⁺ cells versus ALDH1^{Bright} cells (Spearman r=0.2, p=0.02).



Supplementary Figure 5:

Representative CFSE dilution FACS analysis of splenocytes stimulated with a-CD3 and cultured alone or in the presence of tumor conditioned medium (TCM) and CD11b⁺ cells from either GCSFR^{-/-} or WT mice.

Graphs depict means \pm SEM with asterisk (*) denoting statistically significant differences between groups defined as p<0.05 by Mann-Whitney test.

<u>Panni et. al.</u> Supplementary Figure 6





Supplementary Figure 6:

A. Tumor growth curves comparing subcutaneous tumor growth, Pan02 by caliper measurements in WT mice and GCSFR^{-/-} mice. Points on curve represent mean values± SEM at indicated time points.

B. Bar graph compares tumor weights of orthotopically implanted Pan02 in WT and GCSFR^{-/-} mice 28 days post injection.

C. Analysis compares tumor myeloid and lymphoid infiltrate by flow cytometry in WT and GCSFR^{-/-}, Pan02 tumor-bearing mice. Mo-MDSC= CD11b⁺/Ly6C^{hi}/ Gr1⁺/ F4/80^{mid}, G-MDSC = CD11b⁺/Gr-1⁺/Ly6G^{hi}/Ly6C^{mid}, T cells= CD45⁺/CD3⁺; TAM= CD45⁺/CD11b⁺/F4/80^{hi}/Ly6C^{low}/MHCII⁺.

D. Analysis compares tumor myeloid infiltrate by flow cytometry in WT tumors. Blue bars show G-MDSC and Mo-MDSC in a small sized KCM tumor (volume= 0.4cm³) and red bars show myeloid cells in large tumor (volume= 1.0cm³).

Graphs depict means \pm SEM with asterisk (*) denoting statistically significant differences between groups defined as p<0.05 by Mann-Whitney test.



HLA-DR

Supplementary figure 7: CD14⁺ cells were isolated from normal human PBMC by magnetic bead isolation and were co-cultured with human PC cell line BxPC3 for 72 hours. Downregulation of HLA-DR expression after tumor exposure; flow-cytometry was performed on CD14⁺ cells (from blood) after 72 hours of co-culture with tumor cells. Representative plots show that approximately 70.5% CD14⁺ cells had high HLA-DR expression when these cells are

incubated in complete medium (CM). After tumor exposure, these cells downregulate HLA-DR expression and 77.4% CD14⁺ cells have low HLA-DR expression.

SUBCUTANEOUS TUMOR GROWTH CURVE



Supplementary Figure 8: Tumor growth curves comparing subcutaneous tumor growth, Panc-1 spheres (with baseline ALDH1 activity) and Panc-1 spheres after co-culture (increased ALDH1 activity) by caliper measurements in NU/J mice. Points on curve represent mean values ± SEM are indicated time points.

<u>Panni et. al.</u> Supplementary Figure 9



Supplementary figure 9:

A. CD14⁺/HLA-DR^{low/-} cells were co-cultured with Panc-1 for 72 hours and ALDH1, CD24 and CD44 staining was performed. Graph shows ALDH1^{Bright} CSCs and CD24⁺, CD44⁺ cells as a percentage of CD45⁻, EpCAM⁺, Pl⁻ cells.

B. Tumor EMT Markers: RT-PCR shows that markers of cell pluripotency and EMT were upregulated in Panc-1 tumor cells after co-culture with CD14⁺/HLA-DR^{low/-} cells.

C. Graph for invasion assays showing that Panc-1 tumor cells have increased invasion through matrigel matrix membrane in the presence of CD14⁺ cells relative to tumor cells alone. Cells per high power field were quantified. Graph depicts the number of invaded cells per high powered field (mean \pm S.E.M of three independent experiments).

D. Inhibition of STAT3 signaling in CD14⁺/HLA-DR^{low/-} cells prevents the increase in ALDH1^{Bright} CSCs in Panc-1 from baseline. Representative flow-cytometry plots show ALDH1^{Bright} CSC population (gated on CD45⁻, EpCAM⁺, PI⁻ cells) which is approximately 13.5% in Panc-1 alone, 20.8% when Panc-1 was co-cultured with CD14⁺/HLA-DR^{low/-} cells and 12.02% when Panc-1 was co-cultured with STATTIC treated CD14⁺/HLA-DR^{low/-} cells. Graph shows that inhibition of STAT3 signaling by STATTIC (20µM) blocks the increase in frequency of ALDH1^{Bright} cells from baseline.

E. Bar graph shows tumor spheroid formation in Panc-1 cells with and without CD14⁺/HLA-DR^{low/-} cells in the co-culture. The mean number of tumor spheroids formatted after 10 days is depicted.

pSTAT3 IN CD11b⁺ CELLS AFTER CO-CULTURE WITH TUMOR CELLS (KCM)





Supplementary Figure 10:

Western blot analysis shows increased phosphorylated STAT3 in CD11b⁺ cells after co-culture with murine tumor cells (KCM).

<u>Panni et. al.</u> Supplementary Figure 11

IL-6 LEVELS IN CD14⁺ CELLS WITH STAT3 INHIBITION



Supplementary Figure 11:

Inhibition of STAT3 signaling by STATTIC (20uM) downregulates the expression of IL-6 in tumor conditioned CD14⁺/HLA-DR^{low/-} cells by RT-PCR.

Bar graph depicts mean± SEM and asterisk (*) denotes statistically significant difference between the two groups p<0.05 by Mann-Whitney test.